Top

Journal of Cancer Survivorship

Published in:

01-08-2017 | Review

Cancer survivorship monitoring systems for the collection of patient-reported outcomes: a systematic narrative review of international approaches

Authors: N Corsini, J Fish, I Ramsey, G Sharplin, I Flight, R Damarell, B Wiggins, C Wilson, D Roder, M Eckert

Published in: Journal of Cancer Survivorship | Issue 4/2017

Abstract

Purpose

This systematic narrative review describes and compares the development and operational approaches of monitoring systems without a clinical care component that collect patient-reported outcome (PRO) data from cancer survivors.

Methods

Searches were conducted using Medline, PubMed, PsycINFO, the Cochrane Library, CINAHL, Scopus, Joanna Briggs Institute EBP Database and Google Scholar (Advanced). Sources of grey literature and websites of relevant organisations were also searched for relevant published and unpublished material. Articles were included if they described the development (including piloting) of monitoring systems with ongoing recruitment that collect PRO at more than one time point, from 6 months post-diagnosis onward.

Results

The initial searches returned 7290 unique citations. After screening titles and abstracts, 39 full-text articles were retrieved for more detailed examination. Eleven articles were included in the review, representing seven international monitoring systems. Systems varied in their scope, implementation process, governance and administration, recruitment and data collection, consent rates, PRO collection, use of PRO and translation strategies.

Conclusions

The most suitable approach for setting-up and implementing a monitoring system for ongoing surveillance will differ depending on the unique requirements, aims and level of resourcing available within a particular context. Better specification and consideration of how PRO data will be used, for what purpose, and by whom, is required to inform effective translational strategies to improve outcomes for cancer survivors.

Implications for Cancer Survivors

The findings from this review may inform the future development of survivorship monitoring systems in varied environments, which in turn may improve practices that lead to better outcomes for survivors.

Available only for authorised users

American Cancer Society. Global Cancer Facts and Figures: 3rd Edn. Atlanta: American Cancer Society 2015.

Torre LA, Siegel RL, Ward EM, Jemal A. Global cancer incidence and mortality rates and trends—an update. Cancer Epidemiol Biomark Prev. 2016;25(1):16–27.CrossRef

Ferlay J, Soerjomataram I, Dikshit R, Eser C, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2014; doi:10.1002/ijc.29210.PubMed

Aziz NM, Rowland JH. Trends and advances in cancer survivorship research: challenge and opportunity. Semin Radiat Oncol. 2003;13(3):248–66.CrossRefPubMed

Grunfeld E, Earle CC, Stovall E. A framework for cancer survivorship research and translation to policy. Cancer Epidemiol Biomark Prev. 2011;20(10):2099–104.CrossRef

de Moor JS, Mariotto AB, Parry C, Alfano CM, Padgett L, Kent EE, et al. Cancer survivors in the United States: prevalence across the survivorship trajectory and implications for care. Cancer Epidemiol Biomark Prev. 2013;22(4):561–70.CrossRef

Aziz NM. Cancer survivorship research: challenge and opportunity. J Nutr. 2002;132(11 Suppl):3494S–503S.PubMed

Food US, Administration D. Guidance for industry patient-reported outcome measures: use in medical product development to support labeling claims. Fed Regist. 2009;74(35):65132–3.

Ganz PA, Land SR, Antonio C, Zheng P, Yothers G, Petersen L, et al. Cancer survivorship research: the challenge of recruiting adult long term cancer survivors from a cooperative clinical trials group. J Cancer Surviv. 2009;3(3):137–47. doi:10.1007/s11764-009-0093-2.CrossRefPubMedPubMedCentral

10.

Glaser AW, Fraser LK, Corner J, Feltbower R, Morris EJ, Hartwell G, et al. Patient-reported outcomes of cancer survivors in England 1–5 years after diagnosis: a cross-sectional survey. BMJ Open. 2013;3(4):e002317.CrossRefPubMedPubMedCentral

11.

Jensen RE, Snyder CF, Abernethy AP, Basch E, Potosky A, Roberts AC, et al. Review of electronic patient-reported outcome systems used in cancer clinical care. Proc Am Soc Clin Oncol. 2013;10(4):e215–22.

12.

Thong MS, Mols F, Stein KD, Smith T, Coebergh JW, van de Poll-Franse LV. Population-based cancer registries for quality-of-life research: a work-in-progress resource for survivorship studies? Cancer. 2013;119(Suppl 11):2109–23. doi:10.1002/cncr.28056.CrossRefPubMed

13.

Arora NK, Hamilton AS, Potosky AL, Rowland JH, Aziz NM, Bellizzi KM, et al. Population-based survivorship research using cancer registries: a study of non-Hodgkin’s lymphoma survivors. J Cancer Surviv. 2007;1(1):49–63. doi:10.1007/s11764-007-0004-3.CrossRefPubMed

14.

Ganz PA, Earle CC, Goodwin PJ. Journal of clinical oncology update on progress in cancer survivorship care and research. J Clin Oncol. 2012;30(30):3655–6.CrossRefPubMed

15.

van de Poll-Franse LV, Horevoorts N, Eenbergen Mv, Denollet J, Roukema JA, Aaronson NK et al. Eenbergen Mv, Denollet J, Roukema JA, Aaronson NK et al. The patient reported outcomes following initial treatment and long term evaluation of survivorship registry: scope, rationale and design of an infrastructure for the study of physical and psychosocial outcomes in cancer survivorship cohorts. Eur J Cancer 2011;47(14):2188–2194. doi:10.1016/j.ejca.2011.04.034.

16.

Lubeck DP, Litwin MS, Henning JM, Carroll PR. Measurement of health-related quality of life in men with prostate cancer: the CaPSURE database. Qual Life Res. 1997;6(5):385–92.CrossRefPubMed

17.

Lubeck DP, Litwin MS, Henning JM, Stier DM, Mazonson P, Fisk R, et al. The CaPSURE database: a methodology for clinical practice and research in prostate cancer. Urology. 1996;48(5):773–7. doi:10.1016/S0090-4295(96)00226-9.CrossRefPubMed

18.

Porten SP, Cooperberg MR, Konety BR, Carroll PR. The example of CaPSURE: lessons learned from a national disease registry. World J Urol. 2011;29(3):265–71. doi:10.1007/s00345-011-0658-3.CrossRefPubMedPubMedCentral

19.

Daly BJ, Douglas SL, Foley H, Lipson A, Liou CF, Bowman K, et al. Psychosocial registry for persons with cancer: a method of facilitating quality of life and symptom research. Psychooncology. 2007;16(4):358–64.CrossRefPubMed

20.

Freeman D, Dickerson G, Perman M. Multi-institutional registry for prostate cancer radiosurgery: a prospective observational clinical trial. Front. 2014;4:369. doi:10.3389/fonc.2014.00369.

21.

Ashley L, Jones H, Forman D, Newsham A, Brown J, Downing A, et al. Feasibility test of a UK-scalable electronic system for regular collection of patient-reported outcome measures and linkage with clinical cancer registry data: the electronic Patient-reported Outcomes from Cancer Survivors (ePOCS) system. BMC Med Inf Decis Mak. 2011;11:66. doi:10.1186/1472-6947-11-66.CrossRef

22.

Ashley L, Jones H, Thomas J, Forman D, Newsham A, Morris E, et al. Integrating cancer survivors' experiences into UK cancer registries: design and development of the ePOCS system (electronic Patient-reported Outcomes from Cancer Survivors). Br J Cancer. 2011;105(Suppl 1):S74–81. doi:10.1038/bjc.2011.424.CrossRefPubMedPubMedCentral

23.

Ashley L, Jones H, Thomas J, Newsham A, Downing A, Morris E, et al. Integrating patient reported outcomes with clinical cancer registry data: a feasibility study of the electronic Patient-Reported Outcomes From Cancer Survivors (ePOCS) system. J Med Internet Res. 2013;15(10):e230. doi:10.2196/jmir.2764.CrossRefPubMedPubMedCentral

24.

Evans SM, Millar JL, Wood JM, Davis ID, Bolton D, Giles GG, et al. The Prostate Cancer Registry: Monitoring patterns and quality of care for men diagnosed with prostate cancer. BJU Int. 2013;111(4 B):E158–E66. doi:10.1111/j.1464-410X.2012.11530.x.CrossRefPubMed

25.

Stirling RG, Evans S, McLaughlin P, Senthuren M, Millar J, Gooi J, et al. The Victorian Lung Cancer Registry pilot: improving the quality of lung cancer care through the use of a disease quality registry. Lung. 2014;192(5):749–58.CrossRefPubMed

26.

Howell D, Fitch M, Bakker D, Green E, Sussman J, Mayo S, et al. Core domains for a person-focused outcome measurement system in cancer (PROMS-Cancer Core) for routine care: a scoping review and Canadian Delphi Consensus. Value Health. 2013;16(1):76–87.CrossRefPubMed

27.

Chaudhry S, Jin L, Meltzer D. Use of a self-report-generated Charlson Comorbidity Index for predicting mortality. Med Care. 2005;43(6):607–15.CrossRefPubMed

28.

Litwin MS, Greenfield S, Elkin EP, Lubeck DP, Broering JM, Kaplan SH. Assessment of prognosis with the total illness burden index for prostate cancer: aiding clinicians in treatment choice. Cancer. 2007;109(9):1777–83.CrossRefPubMed

29.

Sangha O, Stucki G, Liang MH, Fossel AH, Katz JN. The self-administered comorbidity questionnaire: a new method to assess comorbidity for clinical and health services research. Arthritis Care Res (Hoboken). 2003;49(2):156–63.CrossRef

30.

Mor V, Laliberte L, Morris JN, Wiemann M. The Karnofsky performance status scale: an examination of its reliability and validity in a research setting. Cancer. 1984;53(9):2002–7.CrossRefPubMed

31.

Karnofsky DA, Abelmann WH, Craver LF, Burchenal JH. The use of the nitrogen mustards in the palliative treatment of carcinoma. With particular reference to bronchogenic carcinoma. Cancer. 1948;1(4):634–56.CrossRef

32.

Buccheri G, Ferrigno D, Tamburini M. Karnofsky and ECOG performance status scoring in lung cancer: a prospective, longitudinal study of 536 patients from a single institution. Eur J Cancer. 1996;32(7):1135–41.CrossRef

33.

Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol. 1982;5(6):649–56.CrossRefPubMed

34.

Michielsen HJ, De Vries J, Van Heck GL, Van de Vijver FJ, Sijtsma K. Examination of the dimensionality of fatigue: the construction of the fatigue assessment scale (FAS). Eur J Psychol Assess. 2004;20(1):39.CrossRef

35.

Szymanski KM, Wei JT, Dunn RL, Sanda MG. Development and validation of an abbreviated version of the expanded prostate cancer index composite instrument for measuring health-related quality of life among prostate cancer survivors. Urology. 2010;76(5):1245–50.CrossRefPubMedPubMedCentral

36.

Barry MJ, Fowler Jr FJ, O'Leary MP, Bruskewitz R, Holtgrewe H, Mebust W, et al. The American Urological Association symptom index for benign prostatic hyperplasia. The Measurement Committee of the American Urological Association. J Urol. 1992;148(5):1549–57. discussion 64CrossRefPubMed

37.

Rosen R, Cappelleri J, Smith M, Lipsky J, Pena B. Development and evaluation of an abridged, 5-item version of the International Index Of Erectile Function (IIEF-5) as a diagnostic tool for erectile dysfunction. Int J Impot Res. 1999;11(6):319–26.CrossRefPubMed

38.

Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst. 1993;85(5):365–76.CrossRefPubMed

39.

van Andel G, Bottomley A, Fosså SD, Efficace F, Coens C, Guerif S, et al. An international field study of the EORTC QLQ-PR25: a questionnaire for assessing the health-related quality of life of patients with prostate cancer. Eur J Cancer. 2008;44(16):2418–24.CrossRefPubMed

40.

Gujral S, Conroy T, Fleissner C, Sezer O, King P, Avery K, et al. Assessing quality of life in patients with colorectal cancer: an update of the EORTC quality of life questionnaire. Eur J Cancer. 2007;43(10):1564–73.CrossRefPubMed

41.

Sprangers M, Groenvold M, Arraras JI, Franklin J, te Velde A, Muller M, et al. The European Organization for Research and Treatment of Cancer breast cancer-specific quality-of-life questionnaire module: first results from a three-country field study. J Clin Oncol. 1996;14(10):2756–68.CrossRefPubMed

42.

Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatr Scand. 1983;67(6):361–70.CrossRefPubMed

43.

Andresen EM, Malmgren JA, Carter WB, Patrick DL. Screening for depression in well older adults: evaluation of a short form of the CES-D. Am J Prev Med. 1994.

44.

Cella DF, Jacobsen PB, Orav EJ, Holland JC, Silberfarb PM, Rafla S. A brief POMS measure of distress for cancer patients. J Chronic Dis. 1987;40(10):939–42.CrossRefPubMed

45.

Moss-Morris R, Weinman J, Petrie K, Horne R, Cameron L, Buick D. The revised illness perception questionnaire (IPQ-R). Psychol Health. 2002;17(1):1–16.CrossRef

46.

Peterman AH, Fitchett G, Brady MJ, Hernandez L, Cella D. Measuring spiritual well-being in people with cancer: the functional assessment of chronic illness therapy—spiritual well-being scale (FACIT-Sp). Ann Behav Med. 2002;24(1):49–58.CrossRefPubMed

47.

Scheier MF, Carver CS, Bridges MW. Distinguishing optimism from neuroticism (and trait anxiety, self-mastery, and self-esteem): a reevaluation of the life orientation test. J Pers Soc Psychol. 1994;67(6):1063.CrossRefPubMed

48.

Wright E, Kiely M, Johnston C, Smith A, Cull A, Selby P. Development and evaluation of an instrument to assess social difficulties in routine oncology practice. Qual Life Res. 2005;14(2):373–86.CrossRefPubMed

49.

Wright P, Smith AB, Keding A, Velikova G. The social difficulties inventory (SDI): development of subscales and scoring guidance for staff. Psychooncology. 2011;20(1):36–43. doi:10.1002/pon.1705.CrossRefPubMed

50.

Arraras JI, Kuljanic-Vlasic K, Bjordal K, Yun YH, Efficace F, Holzner B, et al. EORTC QLQ-INFO26: a questionnaire to assess information given to cancer patients a preliminary analysis in eight countries. Psycho-Oncology. 2007;16(3):249–54.CrossRefPubMed

51.

Funch DP, Marshall JR, Gebhardt GP. Assessment of a short scale to measure social support. Soc Sci Med. 1986;23(3):337–44.CrossRefPubMed

52.

Lubeck DP, Spitz PW, Fries JF, Wolfe F, Mitchell DM, Roth SH. A multicenter study of annual health service utilization and costs in rheumatoid arthritis. Arthritis Rheum. 1986;29(4):488–93.CrossRefPubMed

53.

Bruce B, Fries JF. The Stanford Health Assessment Questionnaire: a review of its history, issues, progress, and documentation. J Rheumatol. 2003;30(1):167–78.PubMed

54.

Bruce B, Fries JF. The Stanford health assessment questionnaire: dimensions and practical applications. Health Qual Life Outcomes. 2003;1(1):20.CrossRefPubMedPubMedCentral

55.

Bruce B, Fries J. The health assessment questionnaire (HAQ). Clin Exp Rheumatol. 2005;23(5):S14.PubMed

56.

EuroQol Group. EuroQol—a new facility for the measurement of health-related quality of life. Health policy (Amsterdam, Netherlands). 1990;16(3):199.CrossRef

57.

Brooks R. EuroQol: the current state of play. Health policy. 1996;37(1):53–72.CrossRefPubMed

58.

Ware Jr JE, Sherbourne CD. The MOS 36-item short-form health survey (SF-36): I. Conceptual framework and item selection. Med Care. 1992:473–83.

59.

Ware J, Kosinski M, Dewey J. How to score version 2 of the SF-36 health survey. QualityMetric Incorporated: Lincoln, RI; 2000.

60.

Ware Jr JE, Kosinski M, Keller SD. A 12-item short-form health survey: construction of scales and preliminary tests of reliability and validity. Med Care. 1996;34(3):220–33.CrossRefPubMed

61.

Ware J, Kosinski M, Turner-Bowker D, Gandek B. SF-12v2: how to score version 2 of the SF-12 health survey. Lincoln, RI: QualityMetric Incorporated; 2002.

62.

Ferrans CE. Definitions and conceptual models of quality of life. In: Lipscomb J, Gotay C, Snyder C, editors. Outcomes assessment in cancer. Cambridge: Cambridge University Press; 2005. p. 14–31.

63.

Cella DF, Tulsky DS, Gray G, Sarafian B, Linn E, Bonomi A, et al. The functional assessment of cancer therapy scale: development and validation of the general measure. J Clin Oncol. 1993;11(3):570–9.CrossRefPubMed

64.

Avis NE, Smith KW, McGraw S, Smith RG, Petronis VM, Carver CS. Assessing quality of life in adult cancer survivors (QLACS). Qual Life Res. 2005;14(4):1007–23.CrossRefPubMed

65.

Nicolaije KA, Ezendam NP, Vos MC, Pijnenborg JM, Boll D, Boss EA, et al. Impact of an automatically generated cancer survivorship care plan on patient-reported outcomes in routine clinical practice: longitudinal outcomes of a pragmatic, cluster randomized trial. J Clin Oncol. 2015;33(31):3550–9.CrossRefPubMed

66.

Nicolaije KA, Husson O, Ezendam NP, Vos MC, Kruitwagen RF, Lybeert ML, et al. Endometrial cancer survivors are unsatisfied with received information about diagnosis, treatment and follow-up: a study from the population-based PROFILES registry. Patient Educ Couns. 2012;88(3):427–35. doi:10.1016/j.pec.2012.05.002.CrossRefPubMed

67.

Oerlemans S, Issa DE, van den Broek EC, Nijziel MR, Coebergh JWW, Huijgens PC, et al. Health-related quality of life and persistent symptoms in relation to (R-) CHOP14,(R-) CHOP21, and other therapies among patients with diffuse large B-cell lymphoma: results of the population-based PHAROS-registry. Ann Hematol. 2014;93(10):1705–15.CrossRefPubMed

68.

van de Poll-Franse LV, Pijnenborg JM, Boll D, Vos MC, van den Berg H, Lybeert ML, et al. Health related quality of life and symptoms after pelvic lymphadenectomy or radiotherapy vs. no adjuvant regional treatment in early-stage endometrial carcinoma: a large population-based study. Gynecol Oncol. 2012;127(1):153–60.CrossRefPubMed

69.

Sygna K, Johansen S, Ruland CM. Recruitment challenges in clinical research including cancer patients and their caregivers. A randomized controlled trial study and lessons learned. Trials. 2015;16:428. doi:10.1186/s13063-015-0948-y.CrossRefPubMedPubMedCentral

70.

Treweek S, Lockhart P, Pitkethly M, Cook JA, Kjeldstrøm M, Johansen M et al. Methods to improve recruitment to randomised controlled trials: Cochrane systematic review and meta-analysis. BMJ Open. 2013;3(2). doi: 10.1136/bmjopen-2012-002360.

71.

Hunt KJ, Shlomo N, Addington-Hall J. Participant recruitment in sensitive surveys: a comparative trial of 'opt in' versus 'opt out' approaches. BMC Med Res Methodol. 2013;13:3. doi:10.1186/1471-2288-13-3.CrossRefPubMedPubMedCentral

72.

Vellinga A, Cormican M, Hanahoe B, Bennett K, Murphy AW. Opt-out as an acceptable method of obtaining consent in medical research: a short report. BMC Med Res Methodol. 2011;11:40. doi:10.1186/1471-2288-11-40.CrossRefPubMedPubMedCentral

73.

Olver IN. Linking data to improve health outcomes. Med J Aust. 2014;200(7):368–9.CrossRefPubMed

74.

Roder DM, Fong KM, Brown MP, Zalcberg J, Wainwright CE. Realising opportunities for evidence-based cancer service delivery and research: linking cancer registry and administrative data in Australia. Eur J Cancer Care (Engl). 2014;23(6):721–7. doi:10.1111/ecc.12242.CrossRef

75.

Roder D, Creighton N, Baker D, Walton R, Aranda S, Currow D. Changing roles of population-based cancer registries in Australia. Aust Health Rev. 2015;39(4):425–8. doi:10.1071/ah14250.CrossRefPubMed

76.

Ayanian JZ, Jacobsen PB. Enhancing research on cancer survivors. J Clin Oncol. 2006;24(32):5149–53.CrossRefPubMed

77.

Ganz PA. Why and how to study the fate of cancer survivors: observations from the clinic and the research laboratory. Eur J Cancer. 2003;39(15):2136–41.CrossRefPubMed

78.

Beskow LM, Sandler RS, Weinberger M. Research recruitment through US central cancer registries: balancing privacy and scientific issues. Am J Public Health. 2006;96(11):1920.CrossRefPubMedPubMedCentral

79.

Barrett G, Cassell JA, Peacock JL, Coleman MP. National survey of British public's views on use of identifiable medical data by the National Cancer Registry. BMJ. 2006;332(7549):1068–72.CrossRefPubMedPubMedCentral

80.

Smith TG, Castro KM, Troeschel AN, Arora NK, Lipscomb J, Jones SM, et al. The rationale for patient-reported outcomes surveillance in cancer and a reproducible method for achieving it. Cancer. 2016;122(3):344–51. doi:10.1002/cncr.29767.CrossRefPubMed

81.

Calvert M, Blazeby J, Altman DG, Revicki DA, Moher D, Brundage MD. Reporting of patient-reported outcomes in randomized trials: the CONSORT PRO extension. JAMA. 2013;309(8):814–22. doi:10.1001/jama.2013.879.CrossRefPubMed

82.

Calvert M, Blazeby J, Revicki D, Moher D, Brundage M. Reporting quality of life in clinical trials: a CONSORT extension. Lancet. 2011;378(9804):1684–5. doi:10.1016/s0140-6736(11)61256-7.CrossRefPubMed

83.

Brundage M, Blazeby J, Revicki D, Bass B, de Vet H, Duffy H, et al. Patient-reported outcomes in randomized clinical trials: development of ISOQOL reporting standards. Qual Life Res. 2013;22(6):1161–75. doi:10.1007/s11136-012-0252-1.CrossRefPubMed

84.

Basch E, Abernethy AP, Mullins CD, Reeve BB, Smith ML, Coons SJ, et al. Recommendations for incorporating patient-reported outcomes into clinical comparative effectiveness research in adult oncology. J Clin Oncol. 2012;30(34):4249–55. doi:10.1200/jco.2012.42.5967.CrossRefPubMed

85.

Reeve BB, Wyrwich KW, Wu AW, Velikova G, Terwee CB, Snyder CF, et al. ISOQOL recommends minimum standards for patient-reported outcome measures used in patient-centered outcomes and comparative effectiveness research. Qual Life Res. 2013;22(8):1889–905. doi:10.1007/s11136-012-0344-y.CrossRefPubMed

86.

Journal of clinical epidemiology. 2010/08/06 ed 2010. The Patient-Reported Outcomes Measurement Information System (PROMIS) developed and tested its first wave of adult self-reported health outcome item banks: 2005–2008; p. 1179–94.

87.

Cella D, Stone AA. Health-related quality of life measurement in oncology: advances and opportunities. Am Psychol. 2015;70(2):175–85. doi:10.1037/a0037821.CrossRefPubMed

88.

European Organisation for Research and Treatment of Cancer. Assessing QoL of cancer survivors. http://www.eortc.org/research-groups/quality-of-life-group/strategy/. Accessed 2 August 2016.

89.

Pereira J, Green E, Molloy S, Dudgeon D, Howell D, Krzyzanowska MK et al. Population-based standardized symptom screening: cancer care ontario's edmonton symptom assessment system and performance status initiatives. Journal of Oncology Practice. 2014;10(3).

Title: Cancer survivorship monitoring systems for the collection of patient-reported outcomes: a systematic narrative review of international approaches
Authors: N Corsini
J Fish
I Ramsey
G Sharplin
I Flight
R Damarell
B Wiggins
C Wilson
D Roder
M Eckert
Publication date: 01-08-2017
Publisher: Springer US
Published in: Journal of Cancer Survivorship / Issue 4/2017
Print ISSN: 1932-2259
Electronic ISSN: 1932-2267
DOI: https://doi.org/10.1007/s11764-017-0607-2

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusions

Implications for Cancer Survivors

Please log in to get access to this content

Other articles of this Issue 4/2017

National estimates and correlates of secondhand smoke exposure in US cancer survivors

Neuro emotional technique effects on brain physiology in cancer patients with traumatic stress symptoms: preliminary findings

Life beyond a diagnosis of glioblastoma: a systematic review of the literature

Achieving value in mobile health applications for cancer survivors

A pilot randomized trial to prevent sexual dysfunction in postmenopausal breast cancer survivors starting adjuvant aromatase inhibitor therapy

The patients’ experience of a bladder cancer diagnosis: a systematic review of the qualitative evidence

Keynote webinar | Spotlight on antibody–drug conjugates in cancer